Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944484 | 0.85 | L3MBTL1 (0.50) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL28454492 | 0.85 | SLC1A1 (0.39) | L3MBTL1PPARAPPARGLTA4H | |
| SCHEMBL8300754 | 0.82 | L3MBTL1 (0.52) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL7616466 | 0.81 | L3MBTL1 (0.51) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL15320116 | 0.81 | NPSR1 (0.52) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL15318909 | 0.81 | NPSR1 (0.52) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL5182680 | 0.81 | TPSAB1 (0.47) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL1913579 | 0.79 | L3MBTL1 (0.49) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL1913578 | 0.79 | L3MBTL1 (0.49) | L3MBTL1PPARANPSR1HDAC3HDAC1 | |
| SCHEMBL10677943 | 0.79 | L3MBTL1 (0.46) | L3MBTL1PPARANPSR1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992097-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040122234-A1 | Growth Hormone secretagogues | HAUSER KENNETH LEE (US) | 2004-06-24 | — | — | US | disclosed |
| US-6639076-B1 | Such as 2-(2-amino-2-methylpropanoylamino)-n-(1-(2-oxo-1-phenyl-2-pyrrolidinylethyl -4-yl)-4-phenylbutanamide | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1112071-A4 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6329342-B1 | CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1112071-A1 | GROWTH HORMONE SECRETAGOGUES | Eli Lilly & Company (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000010565-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0933365-A2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0898963-A2 | Congestive heart failure treatment | ELI LILLY AND COMPANY (US) | 1999-03-03 | — | — | EP | disclosed |
| WO-1999008699-A1 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999008697-A1 | TREATMENT OF CONGESTIVE HEART FAILURE WITH GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-4055553-A | GLYCINE-ALANINE, POLYPEPTIDE, GROWTH HORMONE RELEASE INHIBITOR ION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122234-A1 | Growth Hormone secretagogues | GHSR, GHRHR, CRH | L3MBTL1 3050/4885PPARA 1477/4885NPSR1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.